natgillin/translations-raw huggingface dataset:
said rotor comprises a rotor stack coupled with said drive shaft and a rotor cage coupled with said rotor stack, and said at least one group of circumferentially spaced inner air ducts formed in said rotor at a radial position close to said drive shaft is formed in said rotor stack. 
- u navedenom rotorskom paketu (32) se u radijalnom položaju blizu navedenog pogonskog vratila (31) nalazi navedena najmanje jedna skupina unutarnjih vodova za zrak (36a), razmještenih po obodu, načinjenih u navedenom rotoru (30).
A dosage form as claimed in claim 1, wherein said particulates comprise oxycodone or hydromorphone, an ethyl acrylate and methyl methacrylate copolymer, ethyl cellulose as rate controlling or modifying agent, stearyl alcohol and/or triethyl citrate as plasticiser, glyceryl dibehenate as lubricant and optionally opioid antagonist. 
Dozni oblik prema patentnom zahtjevu 1, gdje spomenute čestice sadrže oksikodon ili hidromorfon, kopolimer etil akrilata i metil metakrilata, etil celulozu kao agens za kontroliranje brzine ili modificiranje, stearil alkohol i/ili trietil citrat kao plastifikator, gliceril dibehenat kao lubrikant i po izboru opioidni antagonist.
A system according to claim 3, wherein the pump for the circulation of the hot liquid fluid in the preheating hydraulic circuit (112) is the same recirculation pump (P 1) for the circulation of the cooling fluid in the primary hydraulic circuit (12). 
Sustav prema zahtjevu 3, gdje je pumpa za cirkuliranje tekućine u krugu za prethodno zagrijavanje (112) ista recirkulacijska pumpa (P1) za cirkuliranje tekućine za hlađenje u primarnom hidrauličkom krugu (12).
The antisense oligomer according to any one of claims 1 to 3, which is a morpholino oligomer, or a pharmaceutically acceptable salt or hydrate thereof. 
Suprotni oligomer u skladu s patentnim zahtjevom 6, koji je fosforamidat morholino oligomer ili farmaceutski prihvatljiva sol ili hidrat.
a detectable moiety selected from a fluorescent dye, an enzyme, a substrate, a bioluminescent material, a radioactive material, and a chemiluminescent material, and 
odvojivog dijela odabranog između fluorescentne boje, enzima, supstrata, bioluminescentnog materijala, radioaktivnog materijala, ili kemiluminescentnog materijala, ili
An isolated nucleic acid molecule encoding at least one isolated IL-23p19 antibody according to any of claims 1-3. 
Izolirana molekula nukleinske kiseline koja kodira najmanje jedno izolirano IL-23p19 antitijelo prema bilo kojem od patentnih zahtijeva 1-7 1 10-14.
substantially removing the alcohol by-products from the second mixture; and reacting the compound of the Formula V with a suitable sulphonylating agent in situ to form a sulphonate ester in the presence of a suitable base and toluene to form the compound of the Formula IIa. 
(d) većinskog uklanjanja alkoholnih nus-produkata iz druge mješavine, i (6) reakcije spoja prema formuli V sa pogodnim sredstvom za sulfoniranje in situ koji tvore sulfonatni ester u prisutnosti pogodne baze i toluena koji tvore spoj prema formuli Ila.
after the purification, concentrating the long chain polyunsaturated fatty acids at a temperature lower than the boiling point of the solvent and at a pressure lower than 200 mm Hg and then evaporating to dryness under vacuum or inert gas flow. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, koji sadržava, nakon pročišćavanja, koncentriranje dobivenih polinezasićenih spojeva pri temperaturi nižoj od vrelišta otapala 1 pri tlaku nižem od 200 mm Hg, i zatim uparavanje do suhoće pod vakuumom ili protokom inertnog plina.
The composition according to claim 3, wherein the antiviral agent is selected from: ribavirin and amantadine. 
Sastav prema zahtjevu 13, naznačen time, da je spomenuto antivirusno sredstvo odabrano od ribavirina i amantadina.
Administering therapeutic cells according to the methods of the invention may include application of therapeutic cells alone or formulating the therapeutic cells with one or more of the compounds described supra as pharmaceutical compositions and administering the pharmaceutical compositions to an animal subject or host, including a human patient, intranasally to the upper third of the nasal cavity. 
Terapijske stanice namijenjene upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačene time što se navedeno liječenje dodatno sastoji u predobradi gornje trećine nosne šupljine najmanje jednim antibiotikom u djelotvornoj količini prije primjene terapijskih stanica.
The purification factor was 22, and since the purified r-hIL-18BP fraction eluted in a relatively narrow peak (about 15 ml), the volumetric concentration factor increased to 1.7 fold (Table 3, FIG. 1). 
Faktor pročiišćavanja je bio 22, i budući da je frakcija pročišćenog r-hIL-18BP aluirala u relativno uskom peak-u (otprilike 15 ml), volumetrijski faktor koncentriranja se povećao na 1.7 puta (Tablica 3, Slika 1).
An isolated nucleic acid which comprises a nucleotide sequence encoding the target binding member of claim 1. 
Izolirana nukleinska kiselina, naznačena time, da obuhvaća nukleotidnu sekvencu koja kodira ciljani vezni element prema zahtjevu 1.
A combination of (1) a compound of the formula: or a pharmaceutically acceptable salt thereof, (2) a NS5B polymerase inhibitor and (3) a NS3 protease inhibitor, for use in the prophylactic or therapeutic treatment of hepatitis C or a hepatitis C associated disorder. 
o s O ili njegove farmaceutski soli, (2) NS5B polimeraznog inhibitora i (3) NS3 proteaznog inhibitora, za primjenu u profilaktičkom ili terapijskom liječenju hepatitisa C ili poremećaja povezanog sa hepatitisom C. 24.
The fan assembly of claim 1, wherein the opening extends about the axis, and wherein the axis is preferably substantially horizontal when the air outlet is in an untilted position. 
Ventilatorski sustav prema zahtjevu 13, gdje se otvor (38) pruža oko osi (X), i gdje je os (X) poželjno u biti horizontalna kada je izlaz zraka (14) u nenagnutom položaju.
The pharmaceutical composition of claim 5, wherein: 
Spoj patentnog zahtjeva 5 koje je:
Without limitation, examples of stringent conditions include washing conditions 12-20° C. below the calculated Tm of the hybrid under study in, e.g., 2×SSC and 0.5% SDS for 5 minutes, 2×SSC and 0.1% SDS for 15 minutes; 0.1×SSC and 0.5% SDS at 37° C. for 30-60 minutes and then, a 0.1×SSC and 0.5% SDS at 68° C. for 30-60 minutes. 
Bez ograničenja, primjeri za stroge uvjete uključuju ispiranje kod 12-20%C ispod proračunate Tm hibrida o kojem se govori tj. 2 x SSC i 0.5% SDS u trajanju od 5 min, 2 x SSC i 0.1% SDS u trajanju od 15 min; 0.1 x SSC i 0.5% SDS kod 37*C u trajanju od 30-60 min te nakon toga 0.1 x SSC i 0.5% SDS kod 68*C 30-60 min.
The method of claim 3 wherein said second protein of interest is difficult to express under normal culture conditions. The method of claims 1 or 2 wherein instep (B) said cells are initially cultured cell under normal culture conditions and allowing culture to become hyperosmotic, thereby increasing expression of said second protein of interest. 
Postupak u skladu s patentnim zahtjevima 1 ili 2, naznačen time, da su u koraku (B) spomenute stanice na početku stanice u kulturi pod normalnim uvjetima uzgoja, što omogućuje da kultura postane hiperosmotična, čime se povećava 1 ekspresija spomenutog drugog proteina od interesa.
The compound according to claim 1, which is 3-{[3-(1-Benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxy}-3-methylbutan-1-amine, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time da je 3-([3-(1-benzofuran-2-il)imidazol[1,2-b]piridazin-6-illoksi-3-metilbutan-1-amin, ili stereoizomer, tautomer, N-oksid, hidrat, solvat, ili njegova sol, naročito njegova farmaceutski prihvatljiva sol.
a DNA construct which is capable, when transcribed, of forming a hairpin RNA targeting the PS1 gene; 
DNK konstrukt koji je, kad se transkribira, u stanju formirati RNK petlju ciljajući na gen PS1;
This invention is in the field of preparing and formulating interleukin-2 for pharmaceutical use. 
Ovaj se izum odnosi na područje pripremanja i formuliranja interleukina-2 za farmaceutsku uporabu.
The compound for use according to claim 5, or the use according to claim 6, wherein said cancer is selected from the group consisting of: brain (gliomas), glioblastomas, leukemias, lymphomas, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, inflammatory breast cancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, colon, gastric, bladder, head and neck, kidney, lung, liver, melanoma, renal, ovarian, pancreatic, prostate, sarcoma, osteosarcoma, giant cell tumor of bone and thyroid. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 5, ili upotreba u skladu s patentnim zahtjevom 6, naznačeni time što se navedeni rak bira iz skupine koju čine: rak na mozgu (gliomi), glioblastomi, leukemije, limfomi, Bannayan-Zonanin sindrom, Cowdenova bolest, Lhermitte-Duclosova bolest, rak dojke, upalni rak dojke, Wilmsov tumor, Ewingov sarkom, rabdomiosarkom, ependimom, meduloblastom, rak debelog crijeva, rak želuca, rak mokraćnog mjehura, rak glave i vrata, rak bubrega, rak pluća, rak jetre, melanom, rak bubrežnih stanica, rak jajnika, rak gušterače, rak prostate, sarkom, osteosarkom, gigantocelularni tumor kosti i rak štitnjače.
▪ Ab represents an antibody. 
: Ab predstavlja protutijelo.
These components, used downstream of an extruder, are conventional and will hence not be further described. 
Ove komponente, koje se nalaze u smjeru odvijanja postupka iza ekstrudera, su konvencionalne i zbog toga ne će biti dalje opisivane.
The method of claim 1, wherein the cumulative total amount of asparagine per unit volume in said medium is greater than 8 mM. 
Postupak prema Zahtjevu 1, što je kumulativna ukupna količina asparagina po jedinici volumena u spomenutom mediju veća od približno 8 mM.
Dry powder comprising thyroid hormone (same composition as in example 2 of U.S. Pat. 
Priredi se suhi prah koji sadrži tiroidni hormon (isti sastav kao u primjeru 2 US-B1-6646007).
CX-REED In some embodiments, the methods of the disclosure furthermore comprises step e), wherein step e) comprises removing at least part of one cation from the AX-REED liquid, while retaining at least 65% of said at least one micro-nutrient in said liquid, wherein said cation is removed through an Cation Exchange Reverse Electro-Enhanced Dialysis (CX-REED) membrane stack, said membrane stack containing 
IV. inkubiranje navedene početne tekućine u navedenoj komori, pri čemu se smjer električnog polja preokreće u intervalima i korak e) obuhvaća uklanjanje barem dijela jednog kationa iz početne tekućine ili iz djelomično obrađene tekućine AX-REED, te se tako dobiva tekućina REED, pri čemu se navedeni kation uklanja putem stoga membrana za kationsku izmjenu reverznom elektro poboljšanom dijalizom,,Cation Exchange Reverse Electro-Enhanced Dialysis" (CX-REED), te navedeni stog membrana sadrži i)
admixing water to said cocoa-derived material under aseptic conditions, while optionally also adding other ingredients such as sugar and/or CO2, and 
dodavanje vode uz miješanje u navedenu tvar dobivenu iz kakaa u aseptičnim uvjetima, te po izboru dodavanje drugih sastojaka poput šećera i/ili CO2, i
A method of treating cancer comprising administering to a mammal having cancer a therapeutically effective amount of the compound of claim 1 wherein the cancer is leukemia. 
Spoj sukladno bilo kojem od zahtjeva 1 do 17, naznačen time, da se upotrebljava u postupku liječenja raka, postupak se sastoji u primjeni na sisavcu koji ima rak terapeutski učinkovite količine spoja.
A composition according to claim 1 wherein the pharmaceutically acceptable salt of Clopidogrel is selected from the group consisting of Clopidogrel hydrogensulphate, Clopidogrel hydrobromide, Clopidogrel hydrochloride, Clopidogrel besylate and Clopidogrel mesylate. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što se farmaceutski prihvatljivu sol klopidogrela bira iz skupine koju čine klopidogrela-hidrogensulfat, klopidogrel-hidrobromid, klopidogrel hidroklorid, klopidogrel-besilat, te klopidogrel-mesilat.
The polypeptide dimer of claim 2, wherein the linker comprises 2 to 50 amino acid residues independently selected from the group consisting of glycine, serine, asparagine, threonine and alanine 
Polipeptidni dimer prema patentnom zahtjevu 7, naznačen time što, poveznica je poveznica koja sadrži 2 do 50 aminokiselinskih ostataka nezavisno izabranih iz grupe koja se sastoji od glicina, serina, asparagina, treonina i alanina.
a contiguous sequence of the human λ light chain locus that spans from Vλ3-12 to Vλ3-1; 
graničnu sekvenciju humanog lokusa lakog λ lanca koja se proteže od hVλ3-12 do hVλ3-1;
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of hepatocellular carcinoma and cholangiocarcinoma according to claim 1, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is/are formulated for oral, parenteral, subcutaneous, intravenous, intramuscular, nasal, topical or rectal administration. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, prema zahtjevu 1, naznačene time, da su nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, formulirane za oralnu, parenteralnu, subkutanu, intravenoznu, intramuskularnu, nazalnu, topikalnu ili rektalnu primjenu.
The composition of claim 1, wherein said composition contains fewer than about 1 contaminating parent bacterial cell per 1011 minicells. 
Sastav zahtjeva 1, naznačeno time da sastav sadrži manje od oko 1 kontaminirane bakterijske stanice majke na 10¹¹ ministanica.
THCV alone or in combination with CBD for use in the treatment of generalised seizures and / or partial seizure as claimed in claim 1 or 2 wherein the THCV is present in amount which provides a daily dose of least 15mg. 
CBD za primjenu u liječenju parcijalnih napadaja prema zahtjevu 4, naznačen time da je THCV prisutan u količini koja osigurava dnevnu dozu od najmanje 1,5 mg.
A combination of lipophilic extracts of Zingiber officinale and Echinacea angustifolia for use in the treatment of itching; peripheral pain; superficial or deep inflammatory and painful conditions; pain connected with muscular spasms; herpes pain; radiodermatitis induced by oncological radiotherapy, with or without fungal or bacterial infections; oedema and irritative skin conditions, including those due to excessive exposure to sunlight. 
Kombinacija lipofilnih ekstrakata Zingiber officinale i Echinacea angustifolia za upotrebu u liječenju svrbeži, periferne boli, površinskih ili dubokih upala i bolnih stanja, boli povezanih s mišićnim spazmama, boli urokovanih herpesom, radiodermatitisa induciranog onkološkom radioterapijom sa ili bez gljivičnih ili bakterijskih infekcija, edema ili iritativnih stanja kože uključujući one od pretjeranog izlaganja sunčevu svijetlu.
A method including the following steps a) and b): 
Preparati koji sadrže sljedeće stavke A) i B):
Concerning claim 34, it has to be added that the provision of a plurality of machining elements at the rotational body of the rotary machining tool has the advantage that a particularly plane surface of the planned adhesion surfaces result, whereby the damage of an individual planing element does not directly lead to a worsening of the processing quality. 
Treba dodati da osiguravanje većeg broja elemenata za strojnu obradu na rotirajućem tijelu rotirajućeg alatnog stroja ima prednost što se dobiva naročito ravna površina izravnane površine na koju se nanosi ljepilo, pri čemu oštećenje pojedinog elementa za ravnanje direktno ne dovodi do pogoršanja kvalitete postupka.
The engine of claim 1 wherein the ratio of cylinder volumes from BDC to TDC for either one of the expansion cylinder and compression cylinder is 80 to 1 or greater. 
Motor (100) iz bilo kojeg patentnog zahtjeva od 1 do 9, naznačen time što je omjer volumena cilindra od DMT do GMT za ekspanzijski (104) cilindar ili za kompresijski (106) cilindar približno 80 prema | ili veći.
The series-pipe system or ring-pipe system of claim 1, wherein at least one of the pipe connectors of the first pipe fitting and the second pipe fitting is suitable for connection to a connection element of a concealed fitting. 
Konektor za cijevi (RVS) u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je konektor za cijevi (RVS) pogodan za spajanje sa spojnim elementom (AK) podžbukne armature.
In this example, the duration of the active OFDM symbol may be 448 µs (at 4k FFT mode for 8MHz bandwidth CATV systems) or 597 µs (at 4k FFT mode for 6MHz bandwidth CATV systems). 
Uređaj prema zahtjevu 5, gdje je vrijednost aktivnog OFDM polja trajanja simbola jedna od 448 us na 4k FFT, mod za prijenosni sustav od 8 MHz širine pojasa 1 448 x (8/6) us na 4k FFT mod za prijenosni sustav od 6 MHz širine pojasa.
Wind system (1) according to claim 2, characterised in that said trolley (11) is equipped with wheels (16, 17) to support said trolley (11) weight. 
Vjetreni sustav (1) prema zahtjevu 2, naznačen time da se spomenuti spojler pokreće preko sustava sa samostalnim napajanjem.
a mouse cell infected by a human pathogen, and the therapeutic antibody specifically binds an epitope of the human pathogen; 
(b) mišja stanica zaražena humanim patogenom, a terapijsko antitijelo se specifično vezuje za epitop humanog patogena;
the damaged tissue is damaged by injury or disease; or 
(ili) oštećeno je tkivo oštećeno ozljedom ili bolešću: ili
An Fc-containing molecule having decreased affinity for at least one FcY receptor as compared to a wildtype Fc, comprising an antibody Fc domain with a mutated IgG constant region, wherein amino acid residues 234, 235 and 237 defined by the EU numbering system comprise AAA. 
Molekula koja sadrži Fc koji ima smanjen afinitet za najmanje jedan FcY receptor u usporedbi sa Fc divljeg tipa, sadržavajući Fc domenu antitijela sa mutiranom IgG2 konstantnom regijom, pri čemu su aminokiselinski ostaci 233, 234, 235, 237, i 238 definirani EU sistemom numeracije, obuhvaćajući sekvencu izabranu iz PAAAS (SEQ ID NO:5), i SAAAS (SEQ ID NO:6).
The rotating machine according to claim 15, comprising at least another pendulum, wherein the base (3) is common to the pendulum and the at least another pendulum (4). 
Rotacijski stroj prema jednom od patentnih zahtjeva od 15 do 20, naznačen time da je postolje (3) zajedničko svim polugama (4).
The present invention provides a bifunctional molecule comprising a polypeptide binding partner specific for a given pMHC epitope, and an immune effector polypeptide, the N-terminus of the pMHC binding partner being linked to the C-terminus of the immune effector polypeptide, PROVIDED THAT the said polypeptide binding partner is not a T-cell receptor comprising the alpha chain SEQ ID No: 7 and the beta chain SEQ ID No: 9, wherein the immune effector polypeptide is a cytokine. 
PATENTNI ZAHTJEVI Po ona m Bifunkcionalna molekula koja sadrži polipeptid vezujućeg partnera specifičnog za dani pMHC epitop, i imunološki efektorski polipeptid, gdje je N-kraj pMHC vezujućeg partnera vezan na C-kraj imunološkog efektorskog polipeptida, naznačena time što je polipeptid vezujući partner antitijelo.
A pharmaceutical composition comprising a topical formulation of an isolated compound selected from cycloastragenol, astragenol, astragaloside IV 16-one, cycloastragenol 6-B-D-glucopyranoside and cycloastragenol 3-B-D-xylopyranoside. 
Farmaceutski pripravak, naznačen time što sadrži topikalnu formulaciju izdvojenog spoja koji se bira između cikloastragenola, astragenola, astragalozid IV 16-ona, cikloastragenol 6-B-d-glukopiranozida i cikloastragenol 3-B-d-ksilopiranozida.
The belling machine according to claim 4, characterised in that it comprises a water cooling stage (64) located along the water feed line (61). 
Stroj za oblikovanje u zvono prema zahtjevu 3, naznačen time da sadrži fazu hlađenja vode (64) koja je smještena uzduž linije za uvođenje vode (61).
The rodent of clause 19, wherein the rodent does not express functional endogenous MHC II polypeptides from their endogenous rodent MHC II loci. 
U glodavca iz zahtjeva 7. glodavac na površini stanice ne izražava funkcionalne endogene MHC II polipeptide iz endogenih MHC II lokusa glodavca.
an effective amount of an agent selected from the group consisting of compounds of Formula (I): wherein: • Z is -N- or >CH; 
učinkovitu količinu sredstva koje se bira iz skupine koju čine spojevi formule (I) prema zahtjevu 1 i njihove farmaceutski prihvatljive soli; i
The feed according to any one of claims 15 to 18 obtainable by adding a fatty acid mixture comprising at least 90% palmitic acid to conventional feed ingredients and conventional additives and other auxiliary agents. 
Životinjska hrana prema bilo kojem od zahtjeva 14 do 17 dobivena dodavanjem mješavine masnih kiselina sadržeći barem 90% palmitinske kiseline konvencionanim sastojcima životinjske hrane i konvencionalnim aditivima kao i drugim pomoćnim sredstvima.
A process according to one of the precedent claims wherein X is a chlorine atom. A compound of formula dimethylsulfoxonium-2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-oxoethylide. 
Postupak prema jednom od prethodnih zahtjeva gdje je X atom klora. 10. Spoj formule dimetilsulfoksonij-2-(6-fluor-3,4-dihidro-2H-kromen-2-il)-2-oksoetilid.
A method according to claim 1 comprising administering to a patient a pharmaceutical composition comprising a pharmaceutically effective amount of at least one compound of formula (I), or a pharmaceutically acceptable salt thereof, a physiologically functional derivative thereof and physiologically tolerated excipients and carriers. A method according to claim 21 wherein the pharmaceutical composition further comprises additional additives or other active ingredients. 
Medikament, koji sadrži djelotvornu količinu najmanje jednog spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 33, iili njegove farmakološki prihvatljive soli, fiziološki podnošljive pomoćne tvari i podloge, te, gdje je to prikladno, dodatne aditive i/ili druge aktivne sastojke.
The compound or the pharmaceutically acceptable salt thereof, according to claim 3, wherein R1 is a C1-6 alkyl group (the C1-6 alkyl group may be substituted with the same or different 1 to 3 halogen atoms). 
je skupina C1-4 alkilen ili veza, pri čemu skupina C1-4 alkilen može biti supstituirana s 1 do 4 supstituenata koji su isti ili različiti i odabrani su iz skupine supstituenata, Rc, koji će biti prikazani niže,
reacting a compound of formula (VI): with an N-halosuccinimide compound and 2-aminobenzophenone of formula (II): wherein R is an alkyl or aryl group, in the presence of an organic solvent, to obtain a reaction mixture; 
S N-halosukcinimidnim spojem 1 2-aminobenzofenonom formule (II): gdje R je alkilna ili arilna skupina, a u prisutnosti organskog otapala radi dobivanja reakcijske smjese;
represents a hydrogen atom, a C1-6 alkyl group or a hydroxy C2-6 alkyl group. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, represented by the following formula (III): wherein 
predstavlja vodikov atom, skupinu C1-6 alkil ili skupinu hidroksi C2-6 alkil ili predstavljen sa slijedećom formulom (III): [image] pri čemu
The formulation for use of claim 19 wherein the formulation is administered (i) subcutaneously to the patient, and/or (ii) by a pre-filled syringe containing the formulation therein. 
Formulacija za uporabu prema zahtjevu 19, naznačena time, da se formulacija primjenjuje (i) subkutano na pacijentu, i/ili (ii) pomoću prethodno napunjene štrcaljke koja u sebi sadrži formulaciju.